Definium Therapeutics, Inc. (DFTX) – What Are Brokerages Saying About This Stock?

Definium Therapeutics, Inc. (NASDAQ:DFTX) has received an average rating of “Moderate Buy” from the twenty-one research firms that are currently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, nineteen have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $66.00.

DFTX has been the topic of a number of recent research reports. Stifel Nicolaus lifted their price objective on shares of Definium Therapeutics from $30.00 to $60.00 and gave the company a “buy” rating in a report on Wednesday, July 8th. Oppenheimer restated an “outperform” rating and set a $75.00 target price on shares of Definium Therapeutics in a report on Monday, September 14th. Wells Fargo & Company raised their target price on shares of Definium Therapeutics from $68.00 to $72.00 and gave the company an “overweight” rating in a research report on Thursday, August 13th. Maxim Group set a $55.00 price target on shares of Definium Therapeutics and gave the company a “buy” rating in a research note on Friday, August 14th. Finally, Bank of America began coverage on shares of Definium Therapeutics in a research note on Tuesday, August 18th. They issued a “buy” rating and a $75.00 price target on the stock.

Definium Therapeutics Stock Up 2.8%

NASDAQ:DFTX opened at $38.10 on Thursday. The company has a debt-to-equity ratio of 0.04, a quick ratio of 6.95 and a current ratio of 6.95. The company has a market cap of $5.12 billion, a PE ratio of -11.11 and a beta of 2.19. Definium Therapeutics has a 52-week low of $10.46 and a 52-week high of $49.70. The stock has a 50-day simple moving average of $38.11 and a 200 day simple moving average of $29.28.

Definium Therapeutics (NASDAQ:DFTX) last announced its earnings results on Thursday, August 6th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.89). On average, sell-side analysts expect that Definium Therapeutics will post -3.08 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CFO Brandi Roberts sold 3,377 shares of the firm’s stock in a transaction dated Friday, September 25th. The stock was sold at an average price of $36.57, for a total value of $123,496.89. Following the completion of the transaction, the chief financial officer owned 394,528 shares in the company, valued at $14,427,888.96. This trade represents a 0.85% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Mark Sullivan sold 14,051 shares of Definium Therapeutics stock in a transaction dated Friday, September 25th. The shares were sold at an average price of $36.57, for a total value of $513,845.07. Following the completion of the sale, the insider directly owned 494,228 shares in the company, valued at approximately $18,073,917.96. This represents a 2.76% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 71,098 shares of company stock worth $2,626,115 over the last 90 days. 2.40% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. raised its holdings in shares of Definium Therapeutics by 28.8% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 27,517 shares of the company’s stock valued at $1,051,000 after purchasing an additional 6,159 shares during the period. Pinnacle Wealth Planning Services Inc. lifted its stake in Definium Therapeutics by 2,928.0% in the 3rd quarter. Pinnacle Wealth Planning Services Inc. now owns 757 shares of the company’s stock valued at $29,000 after purchasing an additional 732 shares during the last quarter. Heritage Wealth Management Inc. CA lifted its stake in Definium Therapeutics by 3.3% in the 3rd quarter. Heritage Wealth Management Inc. CA now owns 12,400 shares of the company’s stock valued at $472,000 after purchasing an additional 400 shares during the last quarter. Moody Aldrich Partners LLC grew its holdings in Definium Therapeutics by 191.8% during the third quarter. Moody Aldrich Partners LLC now owns 148,870 shares of the company’s stock worth $5,666,000 after purchasing an additional 97,845 shares during the period. Finally, Kingswood Wealth Advisors LLC grew its holdings in Definium Therapeutics by 2.0% during the third quarter. Kingswood Wealth Advisors LLC now owns 32,065 shares of the company’s stock worth $1,220,000 after purchasing an additional 621 shares during the period. 27.91% of the stock is currently owned by institutional investors.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.